Nephrology

Other nephrology experience

  • Payer objection handlers to support treatment in secondary hyperparathyroidism (SHPT)
  • Consultation on an FDA PRO claim in nephrology
  • COA strategies to complement a biology and renal/fibrotic portfolio
  • Qualitative literature and instrument review in atypical Haemolytic Uremic Syndrome (aHUS)

Kidney (renal) disease

  • Core value dossier for a treatment used in stages III, IV and V renal disease
  • Core value dossier in the treatment of secondary hyperparathyroidism associated with chronic kidney disease including end stage renal disease
  • Core value dossier in chronic kidney disease and end stage renal disease
  • Literature review of the burden of depression in hemodialysis patients (in chronic kidney disease)
  • Pilot utility elicitation study in end stage renal disease
  • Logistical costs of changing treatment in chronic kidney disease
  • Capturing costs when switching from one ESA to another for chronic kidney disease in UK hospital trusts
  • Payer research to understand potential pricing and reimbursement in polycystic kidney disease
  • Disease area review, burden of illness and unmet needs in heart failure (and associated renal dysfunction)
  • Meta-analysis of a treatment for chronic kidney disease: trials and PRO endpoints
  • Manuscripts and conference attendance for a treatment in chronic kidney disease
  • FDA meeting support in defence of PRO claims for a treatment for chronic kidney disease
  • Manuscript and advisory board on physical functioning in chronic kidney disease
  • Development of a manuscript and production of two posters on the symptoms of chronic kidney disease when treated with a specific drug
  • Review of a dossier in chronic kidney disease
  • Qualitative interviews, conceptual model and strategic consulting on autosomal dominant polycystic kidney disease (ADPKD)
  • Measures for use in patients with autosomal dominant polycystic kidney and liver disease: development and validation of a symptom measure and validation of a health survey
  • Regulatory consulting on claims with the FDA for a treatment for end stage renal disease (ESRD)
  • Relevance and context of information for a treatment for hyperphosphatemia in patients with chronic kidney disease
  • Preparation of a manuscript on the relevance of pharmacoeconomics studies in renal disease
  • Literature research and assessment of the appetite and activities of daily living in patients with end-stage renal disease